[ad_1]
Morocco’s healthcare sector has undergone remarkable transformation over five years, evolving from a marginal player to one of the most promising segments on the Casablanca Stock Exchange, driven by regulatory reforms and unprecedented public investment.
The “Health 2025” plan, backed by 24 billion dirhams with 14 billion allocated to hospitals alone, marks a decisive break from historical underinvestment. Universal health insurance coverage reaching 70 percent of the population by 2024 has transformed previously limited demand into a captive market, fundamentally altering sector dynamics.
Private clinic numbers surged from 375 in 2020 to 453 in 2024, with their share of national bed capacity jumping from 28 percent to 40 percent. While Morocco’s 12.8 beds per 10,000 inhabitants remains below OECD averages (46 beds), it approaches the MENA average of 15, according to combined data from HCP and the Health Ministry.
Stock market performance reflects this momentum. Akdital’s revenue exceeded 1.6 billion dirhams in 2024 with net profit soaring 52 percent, catalyzing investor interest. Vicenne’s recent IPO, oversubscribed by 37,000 investors with demand exceeding supply by multiple factors, raised 500 million dirhams—a sector record.
Annual investment flows in private healthcare are projected to reach 32.6 billion dirhams by 2025, growing at 12.2 percent annually. This strategic repositioning extends beyond hospitals to industrial segments including biology, imaging, and interventional radiology.
Globally, the U.S. maintains dominance with McKesson reporting $309 billion revenue, while European markets witness consolidation. Novo Nordisk’s $42 billion revenue marks 25 percent growth, driven by diabetes and obesity treatments, confirming healthcare’s status as a strategic investment asset worldwide.
[ad_2]
Source link